Company Overview of Quintessence Biosciences, Inc.
Quintessence Biosciences, Inc., a biopharmaceutical company, develops protein-based anti-cancer compounds and therapeutics. It offers EVade RNase QBI-139, a product for the treatment of breast, colorectal, non-small cell lung, ovarian, pancreatic, and prostate cancers; and products for the treatment of immune/inflammations and autoimmune/anti-coagulation diseases. The company’s products are based on the EVade ribonuclease technology, which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The company was founded in 1999 and is based in Madison, Wisconsin.
3300 Commercial Avenue
Madison, WI 53714
Founded in 1999
Key Executives for Quintessence Biosciences, Inc.
Quintessence Biosciences, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|NYC2012, Inc.||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Quintessence Biosciences, Inc., please visit www.quintbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.